246 related articles for article (PubMed ID: 24577510)
1. Histone deacetylase inhibitor prevents cell growth in Burkitt's lymphoma by regulating PI3K/Akt pathways and leads to upregulation of miR-143, miR-145, and miR-101.
Ferreira AC; Robaina MC; Rezende LM; Severino P; Klumb CE
Ann Hematol; 2014 Jun; 93(6):983-93. PubMed ID: 24577510
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase inhibitor potentiates chemotherapy-induced apoptosis through Bim upregulation in Burkitt's lymphoma cells.
Dos Santos Ferreira AC; Fernandes RA; Kwee JK; Klumb CE
J Cancer Res Clin Oncol; 2012 Feb; 138(2):317-25. PubMed ID: 22131152
[TBL] [Abstract][Full Text] [Related]
3. Dual inhibition of histone deacetylases and phosphoinositide 3-kinases: effects on Burkitt lymphoma cell growth and migration.
Ferreira AC; de-Freitas-Junior JC; Morgado-Díaz JA; Ridley AJ; Klumb CE
J Leukoc Biol; 2016 Apr; 99(4):569-78. PubMed ID: 26561567
[TBL] [Abstract][Full Text] [Related]
4. MiR-331-3p inhibits proliferation and promotes apoptosis by targeting HER2 through the PI3K/Akt and ERK1/2 pathways in colorectal cancer.
Zhao D; Sui Y; Zheng X
Oncol Rep; 2016 Feb; 35(2):1075-82. PubMed ID: 26718987
[TBL] [Abstract][Full Text] [Related]
5. Arsenic trioxide induces apoptosis and G2/M phase arrest by inducing Cbl to inhibit PI3K/Akt signaling and thereby regulate p53 activation.
Li Y; Qu X; Qu J; Zhang Y; Liu J; Teng Y; Hu X; Hou K; Liu Y
Cancer Lett; 2009 Nov; 284(2):208-15. PubMed ID: 19457607
[TBL] [Abstract][Full Text] [Related]
6. l-Asparaginase synergizes with etoposide via the PI3K/Akt/mTOR pathway in Epstein-Barr virus-positive Burkitt lymphoma.
Sang W; Tu D; Zhang M; Qin Y; Yin W; Song X; Sun C; Yan D; Wang X; Zeng L; Li Z; Xu K; Xu L
J Biochem Mol Toxicol; 2022 Aug; 36(8):e23117. PubMed ID: 35757978
[TBL] [Abstract][Full Text] [Related]
7. Shikonin exerts antitumor activity in Burkitt's lymphoma by inhibiting C-MYC and PI3K/AKT/mTOR pathway and acts synergistically with doxorubicin.
Ni F; Huang X; Chen Z; Qian W; Tong X
Sci Rep; 2018 Feb; 8(1):3317. PubMed ID: 29463831
[TBL] [Abstract][Full Text] [Related]
8. Concomitant reduction of c-Myc expression and PI3K/AKT/mTOR signaling by quercetin induces a strong cytotoxic effect against Burkitt's lymphoma.
Granato M; Rizzello C; Romeo MA; Yadav S; Santarelli R; D'Orazi G; Faggioni A; Cirone M
Int J Biochem Cell Biol; 2016 Oct; 79():393-400. PubMed ID: 27620077
[TBL] [Abstract][Full Text] [Related]
9. PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response.
Shepherd C; Banerjee L; Cheung CW; Mansour MR; Jenkinson S; Gale RE; Khwaja A
Leukemia; 2013 Mar; 27(3):650-60. PubMed ID: 23038273
[TBL] [Abstract][Full Text] [Related]
10. Low expression of miR-150 in pediatric intestinal Burkitt lymphoma.
Wang M; Yang W; Li M; Li Y
Exp Mol Pathol; 2014 Apr; 96(2):261-6. PubMed ID: 24613688
[TBL] [Abstract][Full Text] [Related]
11. TP53 pathway analysis in paediatric Burkitt lymphoma reveals increased MDM4 expression as the only TP53 pathway abnormality detected in a subset of cases.
Leventaki V; Rodic V; Tripp SR; Bayerl MG; Perkins SL; Barnette P; Schiffman JD; Miles RR
Br J Haematol; 2012 Sep; 158(6):763-71. PubMed ID: 22845047
[TBL] [Abstract][Full Text] [Related]
12. Synergistic activity of bortezomib and HDACi in preclinical models of B-cell precursor acute lymphoblastic leukemia via modulation of p53, PI3K/AKT, and NF-κB.
Bastian L; Hof J; Pfau M; Fichtner I; Eckert C; Henze G; Prada J; von Stackelberg A; Seeger K; Shalapour S
Clin Cancer Res; 2013 Mar; 19(6):1445-57. PubMed ID: 23357978
[TBL] [Abstract][Full Text] [Related]
13. Replacement treatment with microRNA-143 and -145 induces synergistic inhibition of the growth of human bladder cancer cells by regulating PI3K/Akt and MAPK signaling pathways.
Noguchi S; Yasui Y; Iwasaki J; Kumazaki M; Yamada N; Naito S; Akao Y
Cancer Lett; 2013 Jan; 328(2):353-61. PubMed ID: 23104321
[TBL] [Abstract][Full Text] [Related]
14. Lack of BIC and microRNA miR-155 expression in primary cases of Burkitt lymphoma.
Kluiver J; Haralambieva E; de Jong D; Blokzijl T; Jacobs S; Kroesen BJ; Poppema S; van den Berg A
Genes Chromosomes Cancer; 2006 Feb; 45(2):147-53. PubMed ID: 16235244
[TBL] [Abstract][Full Text] [Related]
15. Signal transduction pathways in Burkitt's lymphoma cell lines BL41 and DG75 with different sensitivity to doxorubicin.
Shlapatska LM; Berdova GG; Kovalevska LM; Kulyk GI; Klein G; Sidorenko SP; Chekhun VF
Exp Oncol; 2004 Sep; 26(3):210-6. PubMed ID: 15494689
[TBL] [Abstract][Full Text] [Related]
16. Antiproliferative function of p27kip1 is frequently inhibited in highly malignant Burkitt's lymphoma cells.
Barnouin K; Fredersdorf S; Eddaoudi A; Mittnacht S; Pan LX; Du MQ; Lu X
Oncogene; 1999 Nov; 18(46):6388-97. PubMed ID: 10597239
[TBL] [Abstract][Full Text] [Related]
17. Galloflavin suppresses lactate dehydrogenase activity and causes MYC downregulation in Burkitt lymphoma cells through NAD/NADH-dependent inhibition of sirtuin-1.
Vettraino M; Manerba M; Govoni M; Di Stefano G
Anticancer Drugs; 2013 Sep; 24(8):862-70. PubMed ID: 23797802
[TBL] [Abstract][Full Text] [Related]
18. Effect of trichostatin A on Burkitt's lymphoma cells: Inhibition of EPS8 activity through Phospho-Erk1/2 pathway.
Sun P; Zhou X; He Y; Liu H; Wang Y; Chen Y; Li M; He Y; Li G; Li Y
Biochem Biophys Res Commun; 2018 Mar; 497(4):990-996. PubMed ID: 29462617
[TBL] [Abstract][Full Text] [Related]
19. Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels.
Kretzner L; Scuto A; Dino PM; Kowolik CM; Wu J; Ventura P; Jove R; Forman SJ; Yen Y; Kirschbaum MH
Cancer Res; 2011 Jun; 71(11):3912-20. PubMed ID: 21502403
[TBL] [Abstract][Full Text] [Related]
20. miR-10a overexpression is associated with NPM1 mutations and MDM4 downregulation in intermediate-risk acute myeloid leukemia.
Ovcharenko D; Stölzel F; Poitz D; Fierro F; Schaich M; Neubauer A; Kelnar K; Davison T; Müller-Tidow C; Thiede C; Bornhäuser M; Ehninger G; Brown D; Illmer T
Exp Hematol; 2011 Oct; 39(10):1030-1042.e7. PubMed ID: 21784052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
